866-997-4948(US-Canada Toll Free)

Methotrexate (Head and Neck Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Head and Neck Cancer

No. of Pages : 43 Pages

 

GlobalDatas pharmaceuticals report, Methotrexate (Head and Neck Cancer )-Analysis and Forecasts to 2020 provides Methotrexate sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Head and Neck Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Methotrexate including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Methotrexate including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Methotrexate in the US and EU5

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 7
2.4 GlobalData Analysis and Forecasts Report Guidance 9


3 Head and Neck Cancer Disease: Market Characterization 10
3.1 Head and Neck Cancer Disease Market 10
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 10
3.3 Drivers for the Head and Neck Cancer Disease Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 High Mortality 12
3.3.4 Low Initial Diagnosis Rate 12


4 TNM Classification of Head and Neck cancer 13


5 Methotrexate 21
5.1 Introduction 21
5.2 Mechanism of Action 21
5.3 Clinical Studies 21
5.3.1 Dose Response Evaluation 21
5.3.2 Liverpool Head and Neck Oncology Group Trial 23
5.4 Leucovorin Rescue 24
5.4.1 Results 24
5.5 Factors impacting Sales 25
5.5.1 Head and Neck Cancer Market 25
5.5.2 Better Efficacy 25
5.5.3 High Competition 26
5.6 Drug Evaluation 26
5.6.1 Drug Risk Benefit Score 26
5.6.2 Intensity of Competition 27
5.7 Sales forecast 28
5.7.1 Target patient Pool of Methotrexate 28
5.7.2 Dosing 28
5.7.3 Market Penetration 28
5.7.4 Annual Cost of Therapy 29
5.7.5 Sales Projections of Methotrexate 29


6 Head and Neck Cancer Market: Appendix 38
6.1 Market Definitions 38
6.2 Abbreviations 38
6.3 Research Methodology 38
6.3.1 Coverage 39
6.3.2 Secondary Research 39
6.3.3 Forecasting 39
6.3.4 Number of Patients Approved to take the Drug 40
6.3.5 Net Penetration of Drug 40
6.3.6 Net Annual Dosing 42
6.3.7 Annual Cost of Therapy 42
6.3.8 Primary Research 42
6.3.9 Expert Panels 42
6.4 Contact Us 42
6.5 Disclaimer 43
6.6 Sources 43

List of Table


Table 1:Head and Neck Cancer Incidences and Mortality, 2008-2030 5
Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 20092020 10
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypo pharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5:Patients response by initial methotrexate dose 22
Table 6:Reason to failure to complete initial four courses of methotrexate 22
Table 7:Toxicity of methotrexate treatment according to dose 22
Table 8:Comparison of Response rates: Cisplatin, Methotrexate and Combinations 23
Table 9:Result of therapy:MTX+LR 25
Table 10:Drug Risk Benefit Score of Methotrexate 26
Table 11: Head and Neck Cancer, Global, Estimated Sales of Methotrexate($m), 2002-2020 31
Table 12: Head and Neck Cancer, the US, Estimated Sales of Methotrexate($m) 2002-2020 31
Table 13: Head and Neck Cancer, the UK, Estimated Sales of Methotrexate($m) 2002-2020 32
Table 14: Head and Neck Cancer, France, Estimated Sales of Methotrexate($m) 2002-2020 33
Table 15: Head and Neck Cancer, Germany, Estimated Sales of Methotrexate($m) 2002-2020 34
Table 16: Head and Neck Cancer, Italy, Estimated Sales of Methotrexate($m) 2002-2020 35
Table 17: Head and Neck Cancer, Spain, Estimated Sales of Methotrexate($m) 2002-2020 36
Table 18: Head and Neck Cancer, Japan, Estimated Sales of Methotrexate($m) 2002-2020 37

List of Chart


Figure 1: Top 20 Cancers based on Incidence Global, 2008 5
Figure 2: Top 20 Cancers based on Mortality Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 6
Figure 4: Percentage Distribution of various Cancer types in HNC considering US, EU-5 and Japan incidence, 2008 7
Figure 5: Percentage Distribution of various Cancer types in HNC considering Global incidence, 2008 7
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 8
Figure 7: HNC, Global, Market Forecasts ($bn), 20092020 10
Figure 8: Head and Neck Cancer Incidence, Global, 2008-2030 11
Figure 9: Oncology Incidence, Global, 2008-2030 12
Figure 10: Broad Classification of HNC 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypo pharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 19
Figure 16: Response rate of different therapy rates of methotrexate 25
Figure 17: Comparison of Complete Response of different Chemo agents 27
Figure 18: Drug Model Diagram of Methotrexate 28
Figure 19: Head and Neck Cancer, Global Estimated Sales of Methotrexate($m) 2002-2020 30
Figure 20: Distribution of Methotrexate sales in Major Countries 30
Figure 21: Head and Neck Cancer, the US, Estimated Sales of Methotrexate($m) 2002-2020 31
Figure 22: Head and Neck Cancer, UK, Estimated Sales of Methotrexate($m) 2002-2020 32
Figure 23: Head and Neck Cancer, France, Estimated Sales of Methotrexate($m) 2002-2020 33
Figure 24: Head and Neck Cancer, Germany, Estimated Sales of Methotrexate($m) 2002-2020 34
Figure 25: Head and Neck Cancer, Italy, Estimated Sales of Methotrexate($m) 2002-2020 35
Figure 26: Head and Neck Cancer, Spain, Estimated Sales of Methotrexate($m) 2002-2020 36
Figure 27: Head and Neck Cancer, Japan, Estimated Sales of Methotrexate($m) 2002-2020 37
Figure 28: GlobalData Methodology 38
Figure 29: Drug Model Diagram 41
Figure 30: Patients Approved for the Drug 41

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *